IRB Barcelona logo

News

Highlighting IRB Barcelona's impact on society

News

Outreach
IRB Barcelona’s Escape Room raises €1300 for research into metastasis
Clara Campàs, founding partner of Asabys Partners, Salvador Aznar-Benitah and Valerie Vanhooren, founders of Ona Therapeutics, and Sergio Pérez, director of Sabadell Venture Capital
Innovation
New strategy to combat metastasis
Institutional
The 2019 IRB Barcelona Alumni Excellence Award goes to Ana Janic
Innovation
Ona Therapeutics, a start -up with great potential
Structure of a blood vessel. Raquel Batlle, IRB Barcelona.
Scientific - Nature Communications
A study demonstrates that p38 protein regulates the formation of new blood vessels in tumours
Proliferative and invasive capacity of tumour cells (centre) compared to normal cells (left) and effect of TRAMETINIB treatment, which reduces the invasive capacity and tumoural load (right). Marco Milán, IRB Barcelona.
Scientific
Researchers at IRB Barcelona manage to selectively eliminate cells that express the oncogene RAS, which is present in 30% of human cancers
The DNAzyme 9DB1, whose catalytically active structure and reaction mechanism was unknown, makes use of a mechanism involving two ions, similar to that used by natural enzymes (J. Aranda, IRB Barcelona).
Scientific
A study from IRB Barcelona describes the reaction mechanism of DNAzymes and opens new propsects in the field of biocatalysers
Scientific - Published in Chem
A study makes a significant contribution to progress in gene therapy efficiency by identifying the source of asymmetry in RNA · DNA hybrids
The androgen receptor helix of polyglutamine becomes increasingly stable as the number (n) of glutamine amino acid residues increases.
Scientific
Researchers at IRB Barcelona discover the structural consequences of the mutation that causes Kennedy disease

Media Mentions

Blog

Do you want to be informed?

Visit our blog.

IRB Blog